挽救性高剂量率近距离放疗:多重假设检验与机器学习分析
本研究分析1998至2009年间52例既往接受过根治性放疗后局部复发前列腺癌、接受挽救性高剂量率近距离放疗(sHDRB)的患者,处方剂量为前列腺及精囊36 Gy分6次。采用分类与回归树、MediBoost和随机森林等机器学习算法识别与生化失败(BF)相关的临床特征。结果显示阳性穿刺针比例≥0.35且初始放疗后无病间期<4.12年的患者sHDRB后失败率为0.75,其余人群为0.38。
要点
- 52例局部复发前列腺癌患者接受sHDRB,处方36 Gy分6次照射前列腺及精囊。
- 阳性穿刺针比例≥0.35且无病间期<4.12年者sHDRB后失败率为0.75,其余人群为0.38。
- 机器学习识别出阳性穿刺针比例≥0.35且无病间期<4.1年可能与sHDRB后生化失败高风险相关。
核心结论
- 使用机器学习识别出阳性穿刺针比例≥0.35且无病间期<4.1年的患者可能与sHDRB后生化失败高风险相关。
研究设计与样本
- 回顾性分析1998至2009年间52例既往根治性放疗后局部复发前列腺癌、接受sHDRB的患者。
- 病理确认局部复发且无转移证据后,前列腺及精囊给予36 Gy分6次。
- 收集16项临床风险特征,采用分类与回归树、MediBoost和随机森林等决策树算法进行机器学习分析。
主要发现
- sHDRB后随访至少5年。
- 阳性穿刺针比例≥0.35且初始放疗后无病间期<4.12年的患者sHDRB后失败率为0.75,其余人群为0.38。
关键数值与推荐
- 生化失败采用Phoenix定义。
- 阳性穿刺针比例≥0.35且无病间期<4.12年者失败率为0.75,其余人群为0.38。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Salvage high-dose-rate brachytherapy (sHDRB) is a treatment option for recurrences after prior radiation therapy. However, only approximately 50% of patients benefit, with the majority of second recurrences after salvage brachytherapy occurring distantly. Therefore, identification of characteristics that can help select patients who may benefit most from sHDRB is critical. Machine learning may be used to identify characteristics that predict outcome following sHDRB. We aimed to use machine learning to identify patient characteristics associated with biochemical failure (BF) following prostate sHDRB. METHODS AND MATERIALS: We analyzed data for 52 patients treated with sHDRB for locally recurrent prostate cancer after previous definitive radiation therapy between 1998 and 2009. Following pathologic confirmation of locally recurrent disease without evidence of metastatic disease, 36 Gy in 6 fractions was administered to the prostate and seminal vesicles. BF following sHDRB was defined using the Phoenix definition. Sixteen different clinical risk features were collected, and machine learning analysis was executed to identify subpopulations at higher risk of BF. Decision tree-based algorithms including classification and regression trees, MediBoost, and random forests were constructed. RESULTS: Patients were followed up for a minimum of 5 years after sHDRB. Those with a fraction of positive cores ≥0.35 and a disease-free interval <4.12 years after their initial radiation treatment experienced a higher failure rate after sHDRB of 0.75 versus 0.38 for the rest of the population. CONCLUSIONS: Using machine learning, we have identified that patients with a fraction of positive cores ≥0.35 and a disease-free interval <4.1 years might be associated with a high risk of BF following sHDRB.
引用
- Valdes G, Chang AJ, Interian Y, et al. Salvage HDR Brachytherapy: Multiple Hypothesis Testing Versus Machine Learning Analysis. Int J Radiat Oncol Biol Phys. 2018. PMID: 29709315. doi:10.1016/j.ijrobp.2018.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。